Background: Rejection continues to be the main cause of renal graft loss. Currently, the gold standard for diagnosis is an allograft biopsy; however, because it is time-consuming, costly, and invasive, the pursuit of novel biomarkers has gained interest. Variation in the expressions of miRNAs is currently considered a probable biomarker for the diagnosis of acute rejection. This study aimed to determine whether miR-150-5p in serum is related to microvascular damage in patients with acute antibody-mediated rejection (ABMR). Methods: A total of 27 patients who underwent renal transplantation (RT) with and without ABMR were included in the study. We performed the quantification of hsa-miR-150-5p, hsa-miR-155, hsa-miR-21, hsa-miR-126, and hsa-miR-1 in plasma by RT-qPCR. The expressions between the groups and their correlations with the histological characteristics of the patients with ABMR were also investigated. Results: miR-150-5p significantly increased in the plasma of patients with rejection (p < 0.05), and the changes in miR-150-5p were directly correlated with microvascular inflammation in the allograft biopsies. Clinical utility was determined by ROC analysis with an area under the curve of 0.873. Conclusions: Our results show that the patients with RT with ABMR exhibited increased expression of miR-150-5p compared to patients without rejection, which could have clinical consequences, as well as probable utility in the diagnosis of ABMR, and bioinformatics may help in unraveling the molecular mechanisms underlying ABMR conditions.
Antibody-mediated rejection (ABMR) remains a major cause of renal graft dysfunction and loss. The histological hallmark of antibody-mediated rejection is progressive tissue damage, in which extracellular matrix turnover plays an important role. This turnover is mainly regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Recent studies suggest that MMP/TIMP imbalance may favor the progression of renal damage, inflammation, and fibrosis, but the utility of these molecules as a biomarker of antibody-mediated turnover has not been fully explored. We measured plasma MMP and TIMP levels by ELISA in 15 patients with antibody-mediated renal transplant rejection and 12 patients without rejection. There was a significant increase in MMP-1, MMP-2, and MMP-3 concentrations in the plasma of patients with rejection, directly correlating with the severity of different renal lesions. In contrast, TIMP-3 levels were elevated in patients without rejection, showing a negative correlation with the severity of histopathological lesions. The concentrations of these molecules demonstrated good diagnostic capacity for patients with rejection. Our results show that MMP-1, MMP-2, MMP-3, and TIMP-3 could be potential biomarkers of rejection.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting millions worldwide with an incidence that rises with age, and it carries a substantially increased risk of ischemic stroke, heart failure, and cognitive decline. Aging is its most important independent risk factor, yet biological rather than chronological age progressively alters the atrial substrate through interactions among cellular and tissue processes that increase susceptibility. Although the mechanisms linking biological aging to AF remain incompletely elucidated, microRNAs (miRNAs) have been implicated. Human studies show age-associated changes in atrial conduction, molecular regulation, and miRNA expression, while experimental models identify modifiable pathways contributing to structural or electrophysiological vulnerability. Within this architecture, miRNAs emerge as context-dependent regulatory and intercellular signaling nodes. Here we identify the missing-edge problem as a central limitation of the field, distinguishing mechanistic evidence from circulating-miRNA biomarker associations, and experimental targetability from clinical efficacy. We propose a model of networked atrial aging in which heterogeneous age-associated cellular states converge on structural and electrophysiological vulnerability. Further studies connecting aging state, miRNA targets, atrial phenotype, and AF within one biological framework are needed to establish causal pathways and enable biomarker and therapeutic translation.
Background: Early identification of patients requiring operative management (OM) after blunt abdominal trauma is critical, yet initial physiological signs may be nonspecific. We sought to develop and internally validate an admission-based prediction model for early emergency department (ED) triage, prior to computed tomography (CT), using routinely available physiological and biochemical parameters. Methods: We conducted a retrospective observational study including adult patients with blunt abdominal trauma who underwent FAST and lactate testing at admission. OM was defined as any abdominal surgical intervention within 24 h to control hemorrhage or repair injury. A multivariable logistic regression model incorporating lactate, heart rate, leukocyte count, and FAST positivity was developed using complete-case data. Lactate diagnostic accuracy was assessed using ROC analysis. Internal validation was performed with 1000 bootstrap resamples. Results: In 81 patients with lactate results, lactate showed good discrimination for OM (AUC 0.815). At ≥3.5 mmol/L, sensitivity was 0.737 (95% CI 0.569–0.866), specificity 0.744 (0.588–0.865), LR+ 2.88, and LR− 0.35. The final logistic model demonstrated an apparent AUC of 0.904 and an optimism-corrected AUC of 0.882. The full model equation and coefficients are provided for reproducibility. Conclusions: Admission lactate, combined with FAST and physiologic measurements, provides useful early-triage information before CT and warrants external validation in larger cohorts.